NCT05941520

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2024-10-10Est. Completion: 2027-08-23

Enrollment target: 80 participants

Locations

City of Hope Comprehensive Cancer Center, Duarte, California, United States
Northwestern University, Chicago, Illinois, United States
University of Kansas Cancer Center, Kansas City, Kansas, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Other microbiome trials you might be interested in

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialPhase 2Recruiting

Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In SituEstrogen Receptor-Positive Breast Carcinoma

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher …

Tucson, United StatesEst. completion Mar 31, 2028

View Trial →

Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up StudyCompleted

Breast Cancer

This study will explore new screening methods for early detection of breast and ovarian cancer in women at high risk for…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.